Today, Benzinga's options scanner identified 8 options transactions for Illumina. This is an unusual occurrence. The ...

Illumina's high-throughput technology enables whole genome sequencing in humans and ... reaching $88.48. Current RSI values indicate that the stock is may be oversold. Next earnings report is ...

GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation ... positioned at $109.55. RSI indicators show the stock to be is currently ...

Learn about our editorial policies The Relative Strength Index (RSI) is one of the most widely used momentum indicators in technical analysis. It helps traders identify overbought and oversold ...

It was no small prize: at the time, producing this modest slab of DNA — less than 1% the length of the Escherichia coli genome — would have cost roughly US$250,000. The company’s aim was to ...

The company has already begun genome-editing elephant cells, and now, as part of its experimental work, it has successfully introduced cold-adaptation traits into mice. The genetically modified ...

Their research mainly focuses on three landmark studies on Hilsa shad, including its sex reversal, whole genome sequencing, and population genomics. For all latest news, follow The Daily Star's ...

3.20% of the stock is currently owned by company insiders. Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs ...

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for ...